aldosterone has been researched along with Colorectal Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tiberio, L | 1 |
| Nascimbeni, R | 1 |
| Villanacci, V | 1 |
| Casella, C | 1 |
| Fra, A | 1 |
| Vezzoli, V | 1 |
| Furlan, L | 1 |
| Meyer, G | 1 |
| Parrinello, G | 1 |
| Baroni, MD | 1 |
| Salerni, B | 1 |
| Schiaffonati, L | 1 |
| McIntyre, WF | 1 |
| Oqab, Z | 1 |
| Seaborn, GE | 1 |
| Hopman, WM | 1 |
| Hammad, N | 1 |
| Baranchuk, A | 1 |
| Pinés Corrales, PJ | 1 |
| González-Albarrán, O | 1 |
| Peralta, M | 1 |
| Roa, C | 1 |
| Antón, T | 1 |
3 other studies available for aldosterone and Colorectal Cancer
| Article | Year |
|---|---|
The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer.
Topics: Adenocarcinoma; Aldosterone; Biomarkers, Tumor; Cell Hypoxia; Colorectal Neoplasms; Disease Progress | 2013 |
Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab.
Topics: Aged; Aldosterone; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Cardiotoxins; Colore | 2016 |
Clinically inapparent adrenal mass in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Adrenal Gland Neoplasms; Adult; Aldosterone; Colonoscopy; Color | 2006 |